A promising method of immunotherapy to treat children with relapsed acute lymphocytic leukemia (ALL) is opening at the University of Wisconsin Carbone Cancer Center and American Family Children's Hospital. The trial is open ...
Feb 25, 2015
0
14
New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes ...
Jul 9, 2013
0
0
Two new cancer studies out of Dalhousie Medical School have shown success in testing safer, less toxic treatments for a rare form of pediatric leukemia called T-cell acute lymphocytic leukemia (T-ALL). The studies were published ...
Apr 17, 2015
0
34
Not only can bone marrow transplants be life-saving for children with acute lymphocytic leukemia, they may also cure peanut allergies. According to research presented during the American College of Allergy, Asthma and Immunology's ...
Nov 8, 2013
0
0
(HealthDay)—Privileged White U.S. citizens have better health outcomes than average U.S. citizens for several health outcomes, but health outcomes are not always better than those in other developed countries, according ...
Dec 29, 2020
0
4
Henry Ford Cancer Institute has treated its first patient with CAR T-cell therapy, an approach that uses engineered cells from a patient's immune system to destroy cancer. The altered cells remain active for years after the ...
Jun 18, 2019
0
3
September is Childhood Cancer Awareness Month, which makes this a good time to learn about three of the most common types of cancers in children: acute lymphocytic leukemia, neuroblastoma and pediatric brain tumors.
Sep 8, 2021
0
18
(HealthDay)—A new T-cell immunotherapy has led to sustained regression in many previously relapsing and treatment-resistant cases of acute lymphoblastic leukemia, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia, ...
Feb 17, 2016
0
5
A new study on how the progression of acute lymphocytic leukemia (ALL) is influenced by the bone marrow environment has demonstrated for the first time that targeting a specialized protein known as osteopontin (OPN) may be ...
Apr 15, 2013
0
0
Almost all patients with a group of blood cancers called B-cell malignancies have two prominent "fingerprints" on the surface of leukemia and lymphoma cancers, called CD22 and CD19, Vallera explained. To develop the drug, ...
Mar 13, 2015
0
8
